All News
Filter News
Found 808,606 articles
-
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/1/2022
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.
-
REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights
8/1/2022
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights.
-
Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
8/1/2022
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a.m. EDT to discuss the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream 0.3% for treatment of plaque psoriasis.
-
Prothena to Report Second Quarter 2022 Financial Results on August 8th
8/1/2022
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets.
-
Annovis Bio to Participate on Alzheimer's Association International Conference Panel
8/1/2022
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference (AAIC).
-
Adicet Bio to Present at Upcoming Investor Conferences
8/1/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.
-
AVROBIO to Participate in Two Upcoming Investor Conferences in August
8/1/2022
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.
-
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
8/1/2022
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.
-
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
8/1/2022
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business update.
-
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
8/1/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.
-
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
8/1/2022
Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.
-
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
8/1/2022
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its second quarter 2022 financial results webcast on Monday, August 8th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
-
Matinas BioPharma to Participate in the BTIG Biotechnology Conference
8/1/2022
Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas, has been invited to participate in a fireside chat at the BTIG Biotechnology Conference on Monday, August 8, 2022, at 2:00 p.m. ET.
-
Miromatrix to Report Second Quarter 2022 Financial Results
8/1/2022
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022.
-
Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022
8/1/2022
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022 after the close of trading on Monday, August 15, 2022.
-
Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights
8/1/2022
Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights.
-
DBV Technologies Reports Second Quarter 2022 Financial Results
8/1/2022
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2022.
-
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
8/1/2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.
-
Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022
8/1/2022
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, following the close of market.
-
Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
8/1/2022
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business overview.